Date: 2014-06-06
Type of information: Development agreement
Compound: manufacturing cell line for the production of al dendritic-cell-targeting vaccine
Company: Antitope, an Abzena company (UK) Baylor Institute for Immunology Research (USA)
Therapeutic area: Technology - Services - Cancer - Oncology
Type agreement: development
Action mechanism:
Disease: head and neck cancer - cervical cancer
Details: * On June 6, 2014, Antitope, an Abzena company, announced that it will develop a manufacturing cell line for the Baylor Institute for Immunology Research (“BIIR”), using its Composite CHO™ technology. BIIR is developing a range of therapeutic vaccines for the treatment of cancer and other diseases, and Antitope will develop a cell line for the production of BIIR’s novel dendritic-cell-targeting vaccine for the treatment of head and neck and cervical cancer. Antitope has developed the Composite CHO™ technology for the generation of stable cell lines producing high yields of proteins and antibodies ready for cGMP manufacture.
Financial terms:
Latest news:
